







Home ▶ All Journals ▶ Financial Analysts Journal ▶ List of Issues ▶ Volume 56, Issue 3 ▶ Real-Options Valuation for a Biotechnolo

Financial Analysts Journal > Volume 56, 2000 - Issue 3

532 9

Views CrossRef citations to date Altmetric

VALUATION

Real-Options Valuation for a Biotechnology Company

David Kellogg & John M. Charnes

Pages 76-84 | Published online: 02 Jan 2019

🗲 Cite this article 💹 https://doi.org/10.2469/faj.v56.n3.2362

Sample our
Economics, Finance,
Business & Industry Journals
>> Sign in here to start your access
to the latest two volumes for 14 days

References

66 Citations

Metrics

Reprints & Permissions

Read this article

Abstract

Many companies in the biotechnology industry have significant valuations despite having no product revenue because their products are in early stages of development. In the past 10–15 years, investors have bid up the stock prices of companies showing

promise

binomial biotechr

develop

initial ne

value

Many co

used to

having r develop We Care About Your Privacy

We and our 842 partners store and/or access information on a device, such as unique IDs in cookies to process personal data. You may accept or manage your choices by clicking below, including your right to object where legitimate interest is used, or at any time in the privacy policy page. These choices will be signaled to our partners and will not affect browsing data. Privacy Policy

We and our partners process data to provide:

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a device. Personalised advertising and content, advertising and content measurement, audience research and services development.

List of Partners (vendors)

Essential Onlinent of an

Show Purpose re value of a market cept, a drug

lespite

f
es of

companies that show promise of developing a blockbuster drug. This phenomenon is

similar to the more recent rise in stock prices of Internet start-up companies, most of which have shown losses throughout their existence.


Methods used in real-options valuation can be used to assess the value investors place on companies with promise but no current revenue. The value of the company is derived from the expected profits of the company's current products and services together with the potential for growth of the company into one with many profitable products and services. Real-options valuation methods can be applied to estimate the value of individual projects, but the problem addressed in our article is how to use real-options valuation models to assess the value of a company when it is viewed as a portfolio of projects.

We explain decision-tree and binomial-lattice methods and use them to the compute the value of a biotechnology company, Agouron Pharmaceutical, as the sum of the values of its current projects. We find each project's real-options value by using the two real-options valuation methods. We then compare our computed values of Agouron with the actual market values at selected points in time during the development of the company's Viracept product, a drug used to treat HIV-positive patients.

Our intention is to illustrate how real-options valuation methods can be used for financial analysis. Because in our analysis we used data based on results from prior studies (primarily, industry averages), the results reflect the value of Agouron under the assumption that its situation matches that of a typical research-intensive pharmaceutical company in the 1980s and early 1990s. We discuss some of the ways in which Agouron's situation differed from that assumed by the models which a securities analyst X worked best to find t in early later stages o rmation stages o than we progress a particular and stock The real urity analyst's es can use the met relative

worth fo

companies can use these methods to increase their understanding of the value of their projects and convey that value to investors. Finally, for academic readers, this case study provides empirical evidence of the usefulness of real-options valuation methodologies.



Information for Open access **Authors** Overview R&D professionals Open journals Editors **Open Select** Librarians **Dove Medical Press** Societies F1000Research Opportunities Help and information Reprints and e-prints Advertising solutions Newsroom Accelerated publication Corporate access solutions Books Keep up to date Register to receive personalised research and resources by email Sign me up Taylor & Francis Group Copyright © 2024 Informa UK Limited Privacy policy Cookies Terms & conditions Accessib

